Stay updated on Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.4.2 and the previous funding/status notice (Revision: v3.4.1) has been removed; this appears to be a routine maintenance update with no impact on study data or user interaction. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T03:08:29.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Site-wide notice about a lapse in government funding and NIH Clinical Center status was added, and the revision updated to v3.4.1 (replacing v3.4.0).
    Difference
    0.4%
    Check dated 2026-02-04T01:23:28.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Minor UI/text changes: a 'Show glossary' option is added; the QC update label now reads 'Last Update Submitted that Met QC Criteria' and a new 'Revision: v3.4.0' tag appears; footer text shows 'No FEAR Act Data'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T00:17:20.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.3.3 to v3.3.4; no study details, eligibility criteria, or locations appear to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:33:05.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Revision: v3.3.3 appears in the page header. The footer now removes the HHS Vulnerability Disclosure link and Revision: v3.3.2.
    Difference
    0.1%
    Check dated 2025-12-23T08:28:34.000Z thumbnail image
  7. Check
    80 days ago
    Change Detected
    Summary
    Revision: v3.3.2 replaces v3.3.1. No changes to the study content, eligibility criteria, or listed locations are apparent.
    Difference
    0.1%
    Check dated 2025-12-01T17:43:25.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page.